$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223019138 Filed on May 25, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$532.3K	$534.0K	$342.5K
YoY Change	97.31%	55.91%	389.26%
% of Gross Profit
Research & Development	$933.4K	$1.011M	$295.9K
YoY Change	1012.88%	241.58%	169.02%
% of Gross Profit
Depreciation & Amortization	$1.480K	$1.488K	$1.450K
YoY Change	2.07%	2.62%	-114.5%
% of Gross Profit
Operating Expenses	$1.466M	$1.545M	$638.4K
YoY Change	314.45%	141.98%	254.67%
Operating Profit	-$1.466M	-$1.545M	-$638.4K
YoY Change	314.46%	141.98%
Interest Expense	-$303.2K	$692.2K	-$116.5K
YoY Change	24.44%	-694.4%	-332.9%
% of Operating Profit
Other Income/Expense, Net	-$718.7K	$569.7K	-$43.44K
YoY Change	194.99%	-1411.33%
Pretax Income	-$2.184M	-$975.1K	-$681.8K
YoY Change	265.72%	43.01%	424.49%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.184M	-$975.1K	-$681.8K
YoY Change	265.72%	43.01%	427.23%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.15	-$0.07	-$0.07
Diluted Earnings Per Share	-$0.15	-$0.07	-$0.05
COMMON SHARES
Basic Shares Outstanding	13.80M shares	13.65M shares	9.312M shares
Diluted Shares Outstanding	14.26M shares	13.64M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.350M	$10.16M	$20.61K
YoY Change	16454.32%	49196.46%
Cash & Equivalents	$5.447M	$7.169M	$405.9K
Short-Term Investments	$2.900M	$2.990M
Other Short-Term Assets	$6.480K	$200.0K	$405.9K
YoY Change	-52.07%	-50.72%
Inventory
Prepaid Expenses	$78.95K	$203.8K
Receivables	$10.00K	$10.00K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.443M	$10.37M	$426.5K
YoY Change	13103.04%	2332.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.622K	$11.10K	$119.5K
YoY Change	-90.66%	-90.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$10.00K	$6.480K
YoY Change	-100.0%	54.32%
Total Long-Term Assets	$393.8K	$64.62K	$126.0K
YoY Change	259.5%	-48.71%
TOTAL ASSETS
Total Short-Term Assets	$8.443M	$10.37M	$426.5K
Total Long-Term Assets	$393.8K	$64.62K	$126.0K
Total Assets	$8.837M	$10.44M	$552.5K
YoY Change	4994.02%	1789.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$90.00K	$450.0K	$691.2K
YoY Change	-82.55%	-34.9%
Accrued Expenses	$140.0K	$180.0K	$143.2K
YoY Change	-22.94%	25.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$140.0K	$1.112M
YoY Change	-100.0%	-87.41%
Long-Term Debt Due	$270.0K	$620.0K	$0.00
YoY Change
Total Short-Term Liabilities	$493.7K	$1.388M	$2.358M
YoY Change	-79.88%	-41.12%
LONG-TERM LIABILITIES
Long-Term Debt	$120.0K	$750.0K	$0.00
YoY Change
Other Long-Term Liabilities	$1.290M	$1.390M	$44.25K
YoY Change	4939.06%	3041.24%
Total Long-Term Liabilities	$1.410M	$2.140M	$44.25K
YoY Change	5407.81%	4736.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$493.7K	$1.388M	$2.358M
Total Long-Term Liabilities	$1.410M	$2.140M	$44.25K
Total Liabilities	$1.901M	$3.530M	$2.402M
YoY Change	-23.31%	46.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.05M	-$9.870M
YoY Change
Common Stock	$155.00	$137.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.936M	$6.906M	-$1.850M
YoY Change
Total Liabilities & Shareholders Equity	$8.837M	$10.44M	$552.5K
YoY Change	4994.02%	1789.13%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.184M	-$975.1K	-$681.8K
YoY Change	265.72%	43.01%	427.23%
Depreciation, Depletion And Amortization	$1.480K	$1.488K	$1.450K
YoY Change	2.07%	2.62%	-114.5%
Cash From Operating Activities	-$1.646M	-$1.338M	-$624.6K
YoY Change	363.13%	114.21%	1149.22%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$62.80K	-$2.954M
YoY Change
Cash From Investing Activities	$62.80K	-$2.954M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-139.2K	$3.044M	525.7K
YoY Change		478.97%	1214.3%
NET CHANGE
Cash From Operating Activities	-1.646M	-$1.338M	-624.6K
Cash From Investing Activities	62.80K	-$2.954M	0.000
Cash From Financing Activities	-139.2K	$3.044M	525.7K
Net Change In Cash	-1.722M	-$1.248M	-98.89K
YoY Change	384.64%	1161.94%	888.9%
FREE CASH FLOW
Cash From Operating Activities	-$1.646M	-$1.338M	-$624.6K
Capital Expenditures			$0.00
Free Cash Flow			-$624.6K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001757499
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q1	us-gaap	Revenues Revenues		usd
CY2022Q1	us-gaap	Revenues Revenues		usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022Q1	SHPH	Finance Fee FinanceFee		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023Q1	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock		usd
CY2022Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023Q1	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
CY2022Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent		usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2022Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest		usd
CY2022Q1	SHPH	Common Stock Issued For Settlement Of Debt And Interest CommonStockIssuedForSettlementOfDebtAndInterest		usd
CY2022Q1	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41488
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Research Court
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 450
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2023Q1	dei	City Area Code CityAreaCode	(240)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	403-4212
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	SHPH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13804787	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7169268	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	203836	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161148	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2991771	usd
CY2023Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	7023	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	10371898	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8578351	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11104	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12592	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	13686	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	6480	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39826	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56122	usd
CY2023Q1	us-gaap	Assets Assets	10436514	usd
CY2022Q4	us-gaap	Assets Assets	8653545	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	139229	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	685473	usd
CY2023Q1	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	617639	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44633	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62823	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1388354	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	975676	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	751692	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1390000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	3530046	usd
CY2022Q4	us-gaap	Liabilities Liabilities	975676	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13654127	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13654127	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13603129	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13603129	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	137	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16776317	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16572622	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9869986	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8894889	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10436514	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8653545	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1010808	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	295915	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	166348	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13769	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	367624	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	328712	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1544780	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	638396	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1544780	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-638396	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	16688	usd
CY2023Q1	SHPH	Finance Fee FinanceFee	104245	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1241000	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	39650	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	38062	usd
CY2023Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	18254	usd
CY2022Q1	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	569683	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43443	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-975097	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-681839	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	25768	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-975097	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-707607	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13635994	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9312170	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	99543	usd
CY2023Q1	SHPH	Financing Fees Allocated To Warrants FinancingFeesAllocatedToWarrants	-8727	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	104547	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8333	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319643	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166533	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1488	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1450	usd
CY2023Q1	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1241000	usd
CY2022Q1	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	39652	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	567297	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129568	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	38062	usd
CY2023Q1	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	20142	usd
CY2023Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	18254	usd
CY2022Q1	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8333	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	166533	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	7023	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	42687	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	15747	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	330729	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-137117	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12500	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	116051	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15986	usd
CY2023Q1	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-74807	usd
CY2022Q1	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	10547	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7206	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1894	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1329	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1337982	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-624607	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	2953709	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2953709	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-546244	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	525715	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	345000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3043756	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	525715	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1247935	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-98892	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	504749	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7169268	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	405857	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	79044	usd
CY2022Q1	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest	16340	usd
CY2023Q1	SHPH	Common Stock Issued For Settlement Of Debt And Interest CommonStockIssuedForSettlementOfDebtAndInterest	104547	usd
CY2023Q1	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	99543	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10022193	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z0opsLs8wIn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_861_zH1sE9k2Xix1" style="font-family: Times New Roman, Times, Serif"><i>Reclassifications</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zp4TulqPKRUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_86B_zyyNZ2nhrj12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying financial statements valuation of derivatives, and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Cash	6107873	usd
CY2022Q4	us-gaap	Cash Cash	5411378	usd
CY2023Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1061395	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3005825	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7169268	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6667000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2991771	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	12889	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	38062	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1390000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3363007	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	145594	shares
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	162557	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	139229	usd
CY2023Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	23328	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	463052	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	127466	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	127466	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	116362	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114874	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11104	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12592	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1488	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1450	usd
CY2023Q1	us-gaap	Lessee Operating Lease Assumptions And Judgments Discount Rate Description LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription	The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of our leases is not readily determinable.
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	6480	usd
CY2023Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The laboratory lease commenced on October 1, 2018, with the first payment due January 1, 2019
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	6480	usd
CY2023Q1	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	20142	usd
CY2023Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	18254	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	17544	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	17544	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	19440	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	18873	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M21D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M21D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	45360	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45360	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	727	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	44633	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021 the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023.
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	426243	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	64917	usd
CY2023Q1	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q1	SHPH	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue	1189000	usd
CY2023Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	2631000	usd
CY2023Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	1390000	usd
CY2023Q1	SHPH	Derivative Liability Recognized As Debt Discounts For Warrants DerivativeLiabilityRecognizedAsDebtDiscountsForWarrants	1189000	usd
CY2023Q1	SHPH	Derivative Liability Recognized As Debt Discounts For Acceleration Option DerivativeLiabilityRecognizedAsDebtDiscountsForAccelerationOption	1442000	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1241000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1390000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	94025	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	39650	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	54375	usd

Files In Submission

Name	View Source	Status
0001493152-23-019138-index-headers.html	Edgar Link	pending
0001493152-23-019138-index.html	Edgar Link	pending
0001493152-23-019138.txt	Edgar Link	pending
0001493152-23-019138-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20230331.xsd	Edgar Link	pending
shph-20230331_cal.xml	Edgar Link	unprocessable
shph-20230331_def.xml	Edgar Link	unprocessable
shph-20230331_lab.xml	Edgar Link	unprocessable
shph-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q2 Form 10-Q Financial Statement

#000149315223019138 Filed on May 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q2 Form 10-Q Financial Statement

#000149315223019138 Filed on May 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph